A multicomponent psychosocial intervention to reduce substance use by adolescents involved in the criminal justice system: the RISKIT-CJS RCT

Simon Coulton,^{1*} Olena Nizalova,² Tracy Pellatt-Higgins,¹ Alex Stevens,² Nadine Hendrie,¹ Catherine Marchand,¹ Rosa Vass,¹ Paolo Deluca,³ Colin Drummond,³ Jennifer Ferguson,⁴ Gillian Waller⁴ and Dorothy Newbury-Birch⁴

 ¹Centre for Health Services Studies, University of Kent, Canterbury, UK
 ²School of Social Policy, Sociology and Social Research, University of Kent, Canterbury, UK
 ³Institute of Psychiatry, Psychology and Neurosciences, King's College London, London, UK
 ⁴School of Social Sciences, Humanities and Law, Teesside University, Middlesbrough, UK

*Corresponding author s.coulton@kent.ac.uk

Disclosure of interests

Full disclosure of interests: Completed ICMJE forms for all authors, including all related interests, are available in the toolkit on the NIHR Journals Library report publication page at https://doi.org/10.3310/FKPY6814.

Primary conflicts of interest: Simon Coulton reports grants from National Institute for Health and Care Research (NIHR) funding streams involving similar research areas and/or populations, including Health Technology Assessment (HTA) 13/86/03, Public Health Research (PHR) 17/44/11, PHR 13/117/02 and Programme Grants for Applied Research (PGfAR) RP-PG-0609-10162. In addition, Simon Coulton declares funding from the Youth Endowment Fund (London, UK) (GR1-EVAL-092102). Simon Coulton and Alex Stevens worked on the development and evaluation of the RISKIT programme delivered in schools and funded by Kent County Council (Kent, UK). Paolo Deluca reports grants from NIHR funding streams involving similar research areas and/or populations, including PHR 13/117/02 and PGfAR RP-PG-0609-10162. In addition, Alex Stevens declares funding from the Ministry of Justice (London, UK) and Drug Science (London, UK). Colin Drummond reports grants from NIHR funding streams involving similar research areas and/or populations, including HTA 13/86/03, PHR 13/117/02 and PGfAR RP-PG-0609-10162. In addition, Colin Drummond is part funded by the NIHR Biomedical Research Centre at South London and Maudsley NHS Trust (London, UK) and the NIHR Collaboration for Leadership in Applied Health Research (Southampton, UK). Dorothy Newbury-Birch reports grants from NIHR funding streams involving similar research areas and/or populations, including PHR 17/44/11, PHR 13/117/02 and PGfAR RP-PG-0609-10162.

Published March 2023 DOI: 10.3310/FKPY6814

Scientific summary

A multicomponent psychosocial intervention to reduce substance Public Health Research 2023; Vol. 11: No. 3 DOI: 10.3310/FKPY6814

NIHR Journals Library www.journalslibrary.nihr.ac.uk

Scientific summary

Background

Adolescence is a critical developmental stage when young people make behavioural and lifestyle choices that have the potential to affect their health and well-being into adulthood. Six per cent of youths aged 14 years and 11% of youths aged 15 years report having used cannabis in the last month, with 2% of 14-year-olds and 4% of 15-year-olds reporting use of a class A substance at least once.

Data from the Juvenile Cohort Study [Wilson E. Youth Justice Interventions – Findings from the Juvenile Cohort Study (JCS). London: Ministry of Justice Analytical Series; 2013] show that 32% of young offenders indicate substance use is, at least in part, a reason for them associating in criminal activity. Substance use is defined as the use of alcohol, traditional illicit substances and legal highs, as well as inappropriate use of prescribed medication. Although the relationship between substance use and criminal activity is complex, it is clearly a major issue in the youth offending population.

To date, systematic reviews of interventions for substance-using offenders in criminal justice system (CJS) environments have not identified a clear evidence-based intervention strategy. Systematic reviews have revealed the paucity of good-quality research in the area and a lack of UK-based studies, with no scientifically rigorous studies focusing on young offenders. Importantly, previous research has identified what has been proven not to work, and this includes focusing on negative aspects of risk and risk abstinence. Promising intervention approaches identified include motivational interviewing and cognitive and socioemotional life skills training. In addition, there is emerging recognition of the importance of providing interventions in a structured manner and, with the young people's preference for peer group interventions, the importance of managing the potentially negative effects of labelling and peer influence. The RISKIT-Criminal Justice System (RISKIT-CJS) programme is a structured psychosocial intervention developed from evidence reviews and co-production with young people. Pilot research work among risk-taking adolescents in school settings found that the intervention was acceptable and associated with significant reductions in substance use.

Objectives

- To conduct a prospective, pragmatic, randomised controlled trial (RCT) to evaluate the clinical
 effectiveness of the RISKIT-CJS intervention in reducing the frequency of substance use, compared
 with treatment as usual (TAU), among substance-using adolescents involved in the CJS.
- To evaluate the cost-effectiveness of the RISKIT-CJS intervention compared with TAU.
- To explore participants' and criminal justice staff's experience of the intervention and the acceptability of the methods employed.
- To assess the fidelity with which the intervention was conducted and to explore the role of fidelity, therapeutic alliance and baseline psychological factors on the outcomes observed.

Methods

The study evaluated the clinical effectiveness of the RISKIT-CJS programme using a prospective, pragmatic RCT. The study was conducted across three settings [i.e. youth offending teams (YOTs), pupil referral units (PRUs) and substance misuse teams] across four geographical areas of England (i.e. South East, London, North West and North East). Embedded within the trial was a comprehensive qualitative

component that explored young people's and stakeholders' perspectives on the acceptability and usefulness of the RISKIT-CJS programme. Young people aged between 13 and 17 years (inclusive) who were eligible and consented were randomised with equal probability to TAU or to TAU augmented with the RISKIT-CJS programme. The RISKIT-CJS programme was a multicomponent psychosocial intervention, which involved two individual sessions, using motivational interviewing approaches, and two group sessions, employing cognitive-behavioural approaches. An initial individual session was followed by two half-day group sessions, delivered over consecutive weeks, followed by a final individual session. The primary end point for the study was at 12 months post randomisation and the primary outcome measure was the frequency of substance use, assessed as per cent days abstinent (PDA) from substances in the past 28 days, derived from the Timeline Followback 28.

Results

Overall, 693 young people were assessed for eligibility into the trial, of whom 505 were eligible and consented. Among the 188 young people who did not participate, the main reason was declining consent (n = 55, 29%). Of the 505 participants, 246 (49%) were randomised to the RISKIT-CJS programme and 259 (51%) were randomised to TAU. At the primary end point, 275 (57%) participants were followed up, 130 (55%) in the RISKIT-CJS arm and 145 (59%) in the TAU arm. The most common substance used was cannabis (used by 76% of young people). Of those participants randomised to the RISKIT-CJS programme, 214 (87%) attended the first face-to-face session, but only 98 (40%) attended the first group session. Overall, 104 (42%) participants attended at least one individual session and one group session and 47 (19%) participants attended all sessions. Over the 12 months of the study, the PDA from substance use increased in both groups, with a median increase from 60.7% to 85.7% in the RISKIT-CJS arm and a median increase from 61.8% to 83.9% in the TAU arm. A fractional regression indicated no difference between the groups in terms of PDA from substance use at month 12 (odds ratio 1.14, 95% confidence interval 0.74 to 1.76). A similar finding was confirmed when missing data were imputed and a per-protocol analysis undertaken. No differences were observed between the groups on secondary outcomes of well-being and quality of life. The health economic analysis found that the RISKIT-CJS programme had a probability of being cost-effective of 69% when a commissioner's willingness-to-pay (WTP) threshold was zero. At an established WTP threshold of £20,000–30,000, the probability that the RISKIT-CJS programme was cost-effective reduced to 60–63%.

The qualitative analysis explored the views of young people who took part in the RISKIT-CJS programme and of stakeholders working in the services in which the programme was delivered. It addressed three key areas: (1) strengths and weaknesses, (2) usefulness and acceptability, and (3) implementation. The data covered 59 interviews with young people, 14 focus groups with young people, 23 interviews with professionals and 18 sets of research field notes. Several young people and stakeholders identified strengths of the programme, including the varied content and delivery styles and the opportunity to discuss issues in a safe and non-judgemental environment. Weaknesses of the programme that were identified included the inappropriateness of the programme for some participants, particularly older participants with entrenched substance use and criminal histories. In terms of usefulness, stakeholders tended to agree that the programme was more useful for the younger end of the cohort. Acceptability from the perspective of young people varied by setting, with those in PRUs, where group interventions are relatively common, considering the intervention more acceptable than those in YOTs.

Analysis of fidelity indicated high levels of fidelity in the delivery of motivational behavioural change interventions. The exploratory analysis of prognostic factors that may affect outcome identified three predictors. Higher score on the SOCRATES-7DS (Stages Of Change Readiness And Treatment Eagerness Scale – 7 Dimension) preparatory stage, that is, an indicator of lower motivational state, predicted lower PDA at month 12. Higher self-efficacy, that is, the confidence to resist substance use, particularly as it related to managing unpleasant emotions and physical discomfort, predicted higher PDA at month 12. When the fidelity measures and therapeutic analysis were included in the model for the RISKIT-CJS arm

only, the findings remained similar; however, there was a strong therapist effect, with strong therapeutic alliance predicting higher PDA at month 12.

Conclusions

The results of the statistical and economic analysis showed no significant differences between the trial arms for any of the primary or secondary outcomes. This finding was consistent when underlying assumptions were varied and missing data imputed. The qualitative findings were more mixed, with those in PRUs finding the intervention the most useful and acceptable and those in YOTs finding the intervention least useful and acceptable.

Trial registration

The trial is registered as ISRCTN77037777.

Funding

This project was funded by the National Institute for Health and Care Research (NIHR) Public Health Research programme and will be published in full in *Public Health Research*; Vol. 11, No. 3. See the NIHR Journals Library website for further project information.

Public Health Research

ISSN 2050-4381 (Print)

ISSN 2050-439X (Online)

Public Health Research (PHR) was launched in 2013 and is indexed by Europe PMC, NCBI Bookshelf, DOAJ, INAHTA and Ulrichsweb™ (ProQuest LLC, Ann Arbor, MI, USA).

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) (www.publicationethics.org/).

Editorial contact: journals.library@nihr.ac.uk

The full PHR archive is freely available to view online at www.journalslibrary.nihr.ac.uk/phr.

Criteria for inclusion in the Public Health Research journal

Reports are published in *Public Health Research* (PHR) if (1) they have resulted from work for the PHR programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.

Reviews in *Public Health Research* are termed 'systematic' when the account of the search appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others.

PHR programme

The Public Health Research (PHR) programme, part of the National Institute for Health and Care Research (NIHR), is the leading UK funder of public health research, evaluating public health interventions, providing new knowledge on the benefits, costs, acceptability and wider impacts of non-NHS interventions intended to improve the health of the public and reduce inequalities in health. The scope of the programme is multi-disciplinary and broad, covering a range of interventions that improve public health.

For more information about the PHR programme please visit the website: https://www.nihr.ac.uk/explore-nihr/funding-programmes/public-health-research.htm

This report

The research reported in this issue of the journal was funded by the PHR programme as project number 14/183/02. The contractual start date was in September 2016. The final report began editorial review in September 2021 and was accepted for publication in April 2002. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The PHR editors and production house have tried to ensure the accuracy of the authors' report and would like to thank the reviewers for their constructive comments on the final report document. However, they do not accept liability for damages or losses arising from material published in this report.

This report presents independent research funded by the National Institute for Health and Care Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, the PHR programme or the Department of Health and Social Care. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the NHS, these of the authors, those of the NHS, the NIHR, the PHR programme or the Department of Health and Social Care.

Copyright © 2023 Coulton *et al.* This work was produced by Coulton *et al.* under the terms of a commissioning contract issued by the Secretary of State for Health and Social Care. This is an Open Access publication distributed under the terms of the Creative Commons Attribution CC BY 4.0 licence, which permits unrestricted use, distribution, reproduction and adaption in any medium and for any purpose provided that it is properly attributed. See: https://creativecommons.org/licenses/by/4.0/. For attribution the title, original author(s), the publication source – NIHR Journals Library, and the DOI of the publication must be cited.

Published by NIHR Journals Library (www.journalslibrary.nihr.ac.uk), produced by Prepress, final files produced by Newgen Digitalworks Pvt Ltd, Chennai, India (www.newgen.co).

NIHR Journals Library Editor-in-Chief

Dr Cat Chatfield Director of Health Services Research UK

NIHR Journals Library Editors

Professor John Powell Consultant Clinical Adviser, National Institute for Health and Care Excellence (NICE), UK, and Professor of Digital Health Care, Nuffield Department of Primary Care Health Sciences, University of Oxford, UK

Professor Andrée Le May Chair of NIHR Journals Library Editorial Group (HSDR, PGfAR, PHR journals) and Editorin-Chief of HSDR, PGfAR, PHR journals

Professor Matthias Beck Professor of Management, Cork University Business School, Department of Management and Marketing, University College Cork, Ireland

Dr Tessa Crilly Director, Crystal Blue Consulting Ltd, UK

Dr Eugenia Cronin Consultant in Public Health, Delta Public Health Consulting Ltd, UK

Dr Peter Davidson Interim Chair of HTA and EME Editorial Board. Consultant Advisor, School of Healthcare Enterprise and Innovation, University of Southampton, UK

Ms Tara Lamont Senior Adviser, School of Healthcare Enterprise and Innovation, University of Southampton, UK

Dr Catriona McDaid Reader in Trials, Department of Health Sciences, University of York, UK

Professor William McGuire Professor of Child Health, Hull York Medical School, University of York, UK

Professor Geoffrey Meads Emeritus Professor of Wellbeing Research, University of Winchester, UK

Professor James Raftery Professor of Health Technology Assessment, School of Healthcare Enterprise and Innovation, University of Southampton, UK

Dr Rob Riemsma Consultant Advisor, School of Healthcare Enterprise and Innovation, University of Southampton, UK

Professor Helen Roberts Professor of Child Health Research, Child and Adolescent Mental Health, Palliative Care and Paediatrics Unit, Population Policy and Practice Programme, UCL Great Ormond Street Institute of Child Health, London, UK

Professor Jonathan Ross Professor of Sexual Health and HIV, University Hospital Birmingham, UK

Professor Helen Snooks Professor of Health Services Research, Institute of Life Science, College of Medicine, Swansea University, UK

Professor Ken Stein Professor of Public Health, University of Exeter Medical School, UK

Professor Jim Thornton Professor of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences, University of Nottingham, UK

Please visit the website for a list of editors: www.journalslibrary.nihr.ac.uk/about/editors

Editorial contact: journals.library@nihr.ac.uk